中国药房2016，Vol.27Issue(5)：650-652,3.DOI:10.6039/j.issn.1001-0408.2016.05.23
尤瑞克林治疗急性分水岭脑梗死患者的疗效观察
Efficacy Observation of Urinary Kallidinogenase in the Treatment of Acute Cerebral Watershed Infarct
摘要
Abstract
OBJECTIVE:To observe clinical efficacy of urinary kallidinogenase in the treatment of acute cerebral watershed in-farct (WSI). METHODS:128 patients with WSI were randomly divided into control group and treatment group,each of the 64 cases. Control group was given Shuxuening 15 ml added into 0.9% Sodium chloride 250 ml,ivgtt,qd;treatment group received urinary kallidinogenase 0.15 PNA added into 0.9% Sodium chloride 100 ml,ivgtt,qd. Both groups were treated for consecutive 14 days. Neurologic impairment score(NIHSS)and clinical efficacy were observed in 2 groups before treatment and 3,7 and 14 days after treatment. The blood specimens were collected after 7 and 14 days treatment,to determine serum levels of TCC. RESULTS:After treatment,NIHSS and total effective rate of treatment group were significantly higher than those of control group,with statis-tical significance(P<0.01). There was no statistical significance in TCC between 2 groups before treatment(P>0.05);7 days af-ter treatment,TCC level of 2 groups increased significantly,to 14 days,and a declive;the treatment group was higher than the control group,with statistical significance (P<0.05). CONCLUSIONS:Urinary kallidinogenase can improve clinical efficacy of WSI significantly,and promote neurologic impairment symptom and TCC levels.关键词
尤瑞克林/分水岭脑梗死/神经功能缺损评分/血清补体Key words
Urinary kallidinogenase/Cerebral watershed infarct/Neurologic impairment score/Serum complement分类
医药卫生引用本文复制引用
王彬,刘洋,李小圆,王靖,张凤云,马福莲,刘淑芹..尤瑞克林治疗急性分水岭脑梗死患者的疗效观察[J].中国药房,2016,27(5):650-652,3.基金项目
牡丹江医学院科学技术研究项目(No.ZS201522) （No.ZS201522）
